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ABSTRACT 
 
 Isothiocyanates (ITCs) are phytochemicals highly expressed in cruciferous 
vegetables and these compounds are associated with the decreased incidence of cancers 
in populations consuming high levels of cruciferous vegetables.  Several individual ITCs 
including phenethyl isothiocyanate (PEITC) inhibit tumor growth and angiogenesis and 
their anticancer activity has been linked to inhibition of cancer cell growth, survival and 
inflammation (NFB).  It has also been demonstrated that PEITC induces reactive 
oxygen species (ROS) and that ROS is largely responsible for PEITC-induced cell death.  
To confirm PEITC-induced cancer cell death we have investigated the mechanism of 
action of PEITC in pancreatic cancer cell lines and PEITC induces ROS and inhibits 
growth and induces apoptosis (PARP cleavage).  In addition, PEITC downregulates 
expression of several gene products including vascular endothelial growth factor 
(VEGF), cyclin D1 (CD1), Bcl2 and survivin and these have previously been reported in 
other studies.  However, since these gene products are all regulated by specificity protein 
(Sp) transcription factors Sp1, Sp3 and Sp4, which are overexpressed in cancer cells and 
tumors, we investigated the effects of PEITC on Sp proteins and observed that PEITC 
decreased expression of Sp1, Sp3 and Sp4 in pancreatic cancer cells.  These results 
demonstrate for the first time that an important underlying mechanism of action of ITCs 
likely involves targeting Sp transcription factors through an ROS-mediated mechanism 
and the pathways required for ITC-induced Sp downregulation were investigated and the 
results are presented in this paper. 
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INTRODUCTION 
Part one 
     Reactive oxygen species (ROS)  
Reactive oxygen species (ROS) are chemically reactive, oxygen-containing 
species and ROS can be classified into two groups: 1) radical ROS and 2) non-radical 
ROS.  Radical ROS include species that contain one or more unpaired electrons in their 
outer molecular orbital and include superoxide (O2
.-), nitric oxide (NO.) and hydroxyl 
(.OH) radicals.  Non-radical ROS do not have any unpaired electrons in their outer 
orbitals, however they are also chemically reactive and can be converted into radical 
ROS.  Examples of non-radical ROS include hydrogen peroxide (H2O2), ozone (O3), 
peroxynitrite (ONOO-) and hydroxide (OH) [1].   
 ROS normally exist in all cells that undergo aerobic respiration.  Endogenous 
sources of ROS in cells includes mitochondria, peroxisomes and cytochrome P450 
enzymes and it has also been reported that membrane-bound NADPH oxidases can 
contribute to endogenous ROS production [2, 3].   Exogenous sources include UV light, 
ionizing radiation, inflammatory cytokines and pathogens.  Although ROS can be 
generated via multiple pathways the majority of cellular ROS comes from mitochondria.   
Mitochondria provide approximately 90% of the energy that cells need to 
function through the generation of ATP from oxidative phosphorylation and most ROS 
produced in mitochondria come from the electron transport chain as a byproduct of 
respiration [4-6].  During oxidative phosphorylation a proton gradient is established 
across the inner mitochondrial membrane by the constant transport of electrons through 
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the electron transport chain.  It has been demonstrated in vitro that NADH 
dehydrogenase, in Complex I of the electron transport chain, is a major entry point for 
electrons and thus is a major site of ROS production [7].  Another major site of ROS 
production in the mitochondria is in Complex III of the electron transport chain.  The 
bc1 complex (ubiquinone: cytochrome c reductase) on the inner side of the inner 
mitochondrial membrane in Complex III generates ROS through the Q-cycle [8].  There 
are other non-respiratory chain mitochondrial enzymes that have been shown to generate 
ROS, however it is difficult to estimate their total contribution of ROS production within 
the mitochondria [9].  It is interesting to note that approximately 2% of the oxygen 
consumed by mitochondria is converted into superoxide and superoxide generated by 
mitochondria can be converted into H2O2 and other ROS [10].  Although mitochondria 
are the primary source of ROS in cells there are also other pathways in the cell that 
generate ROS. 
 Peroxisomes are organelles found in nearly all eukaryotes and their name is 
based on the large number of H2O2-producing oxidases found within this organelle.  
Peroxisomes have been identified as critical organelles that contain greater than 50 
enzymes involved in cellular metabolism.  Peroxisomes participate in such metabolic 
pathways as β-oxidation of very long and long chain fatty acids, leukotrienes, and 
prostaglandins; biosynthesis of cholesterol, bile acids, dolichol and ether lipids; 
oxidation of D-amino acids, polyamines and uric acid; and detoxification of xenobiotics, 
glyoxylate and ROS [11-14].  Peroxisomes are largely responsible for producing H2O2, 
however peroxisomes also produce superoxide and nitric oxide radicals.  For example, 
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H2O2 is produced by acyl-CoA oxidase, an enzyme involved in the β-oxdiation of fatty 
acids [15] and nitric oxide is produced in peroxisomes by nitric oxide synthase which 
catalyzes the oxidation of L-arginine to nitric oxide. Once formed, nitric oxide can 
combine with superoxide to form peroxynitrite, a strong radical [11].  One study showed 
that approximately 35% of all H2O2 produced in rat liver was produced by peroxisomal 
oxidases and this accounts for roughly 20% of all oxygen consumption [16, 17].  
Mitochondria and peroxisomes are therefore largely responsible for the generation of 
ROS in cells.   
 It has also been reported that cytochrome P450 enzymes are capable of 
producing ROS.  Cytochrome P450s (CYPs) are membrane-bound enzymes found in the 
endoplasmic reticulum  and these enzymes are involved in the oxygenation of drugs, 
xenobiotics, carcinogens and endogenous substrates [18].  CYPs are primarily located in 
the liver, however they are also expressed in tissues such as lung, kidney, brain and 
various other organs [19].  CYPs require the input of electrons from the electron donor, 
NADPH, in order to activate oxygen and catalyze substrate oxidation.  The input of 
electrons from NADPH leading to the activation of oxygen is the first step leading to the 
production of ROS.  The catalytic cycle of CYPs, which inserts oxygen into its substrate, 
is a multi-step process and ROS can be generated at three different points in the catalytic 
cycle.  CYP catalyzed addition of oxygen to its substrate relies on the coordination of 
oxygen around the iron atom in the heme group and coordination of oxygen associated 
with the iron atom is critical for ROS production.  The first part of the cycle leading to 
the production of ROS is the release of a superoxide anion due to the decay of the one-
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electron-reduced ternary complex.  The second point of ROS generation is the 
production of H2O2 coming from the protonation of peroxycytochrome P450.  The final 
part of the cycle giving rise to ROS involves the addition of two more electrons 
following the decay of peroxycytochrome P450 resulting in the release of the second 
oxygen atom in the form of water [20].  A schematic representation of ROS production 
by CYPs is illustrated in Figure 1.   
 
 
Figure 1.  Schematic of ROS production within the catalytic cycle of cytochrome P450.  
Sites of ROS production can be seen in blue [20]. 
 
 
The release of ROS from CYP-mediated oxygenation of substrates is an ongoing and 
continual process.  ROS are generated as a result of substrate oxygenation, however the 
amount of ROS produced depends on many factors including the type of substrate, pH of 
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the solution, ionic strength and oxygen concentration [21].  Mitochondria, peroxisomes 
and cytochrome P450s are the primary cellular locations for generation of ROS which 
are highly reactive and can cause cell damage.   
     Targets of ROS  
ROS can directly damage DNA, protein and lipid membranes and this can result 
in disruption of cellular structure and function [22].  The most common type of DNA 
damage is that induced by ROS.  Not surprisingly, mitochondria are very susceptible to 
injury from their endogenous production of ROS [23].  Mitochondrial DNA (mtDNA) is 
located on the inner mitochondrial membrane adjacent to the respiratory chain, the 
primary site of mitochondrial ROS production and mtDNA is particularly susceptible to 
damage from ROS.  MtDNA lacks introns and histones and lacks the high quality DNA 
repair machinery present in nuclear DNA [24].  Both the base and sugar in DNA are 
susceptible to ROS mediated  damage and this can result in oxidized bases, DNA strand 
breaks, DNA intra-strand adducts and DNA-protein crosslinks and hydroxylation of 
pyrimidines at C5 and C6 and purines at C4, C5 and C8 [25, 26].  8-Hydroxy-
deoxyguanosine (8-OHDG) is a reliable marker of ROS-induced effects [27, 28].  
Damage to mtDNA can potentially lead to disruption of the mitochondrial respiratory 
chain which could ultimately lead to increased formation of ROS [29].   
Mitochondrial ROS not only targets mtDNA but also targets proteins and lipids 
within mitochondria.  ROS can cause oxidative damage to proteins thereby inducing the 
formation of protein carbonyls which are commonly detected in aged animal tissues and 
cells.  Oxidative damage to proteins in mitochondria can occur on amino acids such as 
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arginine, lysine, threonine and proline and peroxynitrite oxidizes tryptophan, cysteine 
and tyrosine residues.  Carbohydrates are also susceptible to oxidative damage, which 
can lead to the formation of glycation end products [30].   
It is well known that the mitochondrial respiratory chain generates large amounts 
of superoxide anions due to the large input of electrons needed to generate ATP.  ROS 
can directly affect the respiratory chain by oxidizing iron-sulfur clusters present in 
Complexes I, II and III; heme groups in Complexes II, III and IV; and copper centers in 
Complex IV [31].  Cytochrome c, a component of oxidative phosphorylation, can 
undergo nitration on its tyrosine residues ultimately leading to the disruption of electron 
flow through the respiratory chain [32].  Overall, the damaging effects of ROS on the 
respiratory chain can impair the production of ATP and leads to generation of more ROS 
by oxidizing subunits of oxidative phosphorylation [9].   
Another target of ROS in the mitochondria is the mitochondrial permeability 
transition pore (mPTP).  The mPTP is a multi-protein complex consisting of a voltage-
dependent anion channel (VDAC), adenine dinucleotide translocase (ANT) and 
cyclophilin D located in the inner and outer mitochondrial membrane and the 
mitochondrial matrix [33].  It is well documented that oxidation of thiol residues in ANT 
leads to the opening of the mPTP and subsequently the collapse of mitochondrial 
membrane potential, mitochondrial swelling and cytochrome c release, all of which can 
potentially induce apoptosis [34].   
Finally, lipids and lipid membranes are targets of mitochondria-induced ROS. 
Unsaturated fatty acids present in mitochondrial membranes are also susceptible to 
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oxidation by hydroxyl radicals which are produced in the mitochondria by converting 
H2O2 into the hydroxyl radical using metal ions in what is known as the Fenton reaction 
[35, 36].  The hydroxyl radical is highly reactive and is known to be one of the strongest 
oxidants in nature [9].  Hydroxyl radicals oxidize the unsaturated fatty acids present in 
both mitochondrial lipid membranes and cellular membranes forming lipid 
hydroperoxides which are converted into highly reactive unsaturated aldehydes [35, 36].  
Once formed, lipid hydroperoxides can induce a chain reaction forming new lipid 
hydroperoxides.  Lipid peroxidation affects membrane fluidity by leading to an increase 
in membrane permeability to protons and leading to the uncoupling of oxidative 
phosphorylation [36].  In addition, lipid peroxides are able to diffuse through 
mitochondrial membranes and covalently modify proteins as well as cause oxidative 
damage to mtDNA [37].  Just as proteins and DNA are affected by ROS in 
mitochondria, these same biomolecules can be affected by ROS outside of the 
mitochondria. 
 Superoxide anion radicals generated by mitochondria are converted into H2O2, 
which is membrane permeable and the relatively stable H2O2 molecule enters the 
nucleus.  Upon entering the nucleus H2O2 can be converted into the highly reactive 
hydroxyl radical in the presence of an iron catalyst (Fenton reaction) and the hydroxyl 
radical causes severe oxidative damage to nuclear DNA resulting in mutations that are 
generally found in the form of base pair mismatching during DNA replication or in the 
form of nucleotide insertions [35, 38].  It should also be noted that nuclear DNA is not as 
susceptible to oxidative damage as mtDNA as indicated previously.   
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 Extra-mitochondrial proteins are affected by ROS in the same manner as 
mitochondrial proteins and undergo oxidative modification of amino acid side chains 
and cleavage of peptide bonds [39].  Proteins can undergo nitrosylation by ROS and 
peroxynitrite and this can affect the signaling of such proteins as NF-κB, AP-1 and p53 
resulting in damage to cell function and structure [40].   
     Cellular defense against ROS 
All cells undergoing aerobic respiration, inevitably, will generate ROS as 
byproducts of cellular metabolism and when these natural byproducts of metabolism 
bioaccumulate the resulting oxidative stress induces apoptosis or necrosis.  Cells have 
developed many genes/pathways for regulating ROS levels and these include both 
enzymatic and non-enzymatic mechanisms.  Enzymatic mechanisms include superoxide 
dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT).  Non-enzymatic 
mechanisms include the use of ascorbic acid (Vitamin C), α-tocopherol (Vitamin E), 
glutathione (GSH), carotenoids, flavonoids and others [41].  Both enzymatic and non-
enzymatic mechanisms are critical for maintaining a healthy redox balance to ensure 
cellular survival.  A brief overview of the antioxidant enzymatic mechanisms will be 
discussed below. 
Enzymatic mechanisms 
The primary enzymes responsible for maintaining the redox balance within the 
cell are SOD, catalase and GPx.  SOD catalyzes the dismutation of superoxide into 
oxygen and hydrogen peroxide [42].  There are three forms of SOD found in humans: 
cytosolic Cu/Zn-SOD, mitochondrial Mn-SOD and extracellular SOD (EC-SOD) [43, 
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44].  SOD catalyzes the dismutation of superoxide by oxidation and reduction of the 
transition metal ion at the active site [45].  Mn-SOD contains one Mn atom per subunit 
that cycles between Mn2+ [46] and Mn 3+ [46] [47].  It has been demonstrated that 
cytokines play a pivotal role in induction and repression of Mn-SOD expression and that 
oxidants play only a minor role in regulating the expression of this enzyme [48].  In 
addition, knockdown of Mn-SOD in mice resulted in dilated cardiomyopathy and 
neonatal lethality thus indicating its importance for cellular survival [49].           
 Unlike Mn-SOD, Cu/Zn-SOD is not essential for cellular survival.  Knocking out 
Cu/Zn-SOD in mice has no deleterious effects except after traumatic injury [49].  
Although Cu/Zn-SOD is not an essential enzyme it is believed to play a role in the first 
line of antioxidant defense.  In fact, calves that were fed milk supplemented with 25 ppm 
Cu and 100 ppm Zn exhibited a stronger immune response and showed higher SOD 
activity [43, 50].   
 EC-SOD is a glycoprotein containing both Cu and Zn and has a high affinity for 
glycosaminoglycans including heparin and heparan sulfate.  EC-SOD accounts for the 
majority of SOD activity in plasma and is primarily regulated by cytokines and not 
oxidants [44, 51, 52].   
 Catalase is an enzyme responsible for regulating hydrogen peroxide levels within 
the cell.  Catalase catalyzes hydrogen peroxide cleavage to form water and molecular 
oxygen.  In addition, catalase reacts with various hydrogen donors, such as methanol, 
ethanol, formic acid and phenols, using peroxidase activity.  It has been demonstrated 
that catalase is not essential in some cell types, however it is well understood that 
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catalase plays a critical role in the cellular response to oxidative stress from hydrogen 
peroxide and thus is a critical enzyme for maintaining a redox balance within the cell 
[53]. 
 Glutathione peroxidase (GPx) is a seleno-containing enzyme consisting of one 
selenocysteine residue in each of its four subunits that is essential for its enzyme activity 
[54].  GPx uses glutathione as a cofactor to catalyze the reduction of lipid and other 
organic hydroperoxides and is a major enzyme responsible for protection against 
oxidative stress.  There are five GPx isoenzymes found in mammals and although GPx 
expression is ubiquitous the levels of each isoform vary depending upon tissue type.  
GPx1 is found within erythrocytes, kidney and liver and is responsible for reducing fatty 
acid hydroperoxides and hydrogen peroxide using glutathione as a cofactor [55, 56].  
Levels of GPx2 and GPx3 are low and are only expressed in the gastrointestinal tract and 
kidney, respectively [43, 56].  GPx4 has been detected in the cytosolic and membrane 
fraction from renal epithelial cells and testes and catalyzes reduction of phospholipid 
hydrperoxides, fatty acid hydroperoxides and cholesterol hydroperoxides found in 
peroxidized membranes and oxidized lipoproteins [43, 55, 56].  GPx5 has only recently 
been discovered and is located exclusively in mouse epididymis and is selenium-
independent [56].   
Non-enzymatic mechanisms 
 Glutathione (GSH) is one of the most essential intracellular defense mechanisms 
against ROS-mediated damage [57].  GSH is expressed in high concentrations in various 
cellular compartments including the cytosol (1-11 mM), nuclei (3-15 mM) and 
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mitochondria (5-11 mM) [58].  There are two forms of GSH: reduced GSH (GSH) and 
oxidized GSH (GSSG).  To protect cells from oxidative stress GSH donates an electron 
to an oxidant from a sulfhydryl group resulting in the formation of a disulphide bond 
with another GSH molecule creating an oxidized form (GSSG).  The oxidized GSSG 
does not participate in regulating redox balance until is converted back into its reduced 
form (GSH) [59].  High a concentrations of GSSG can increase the amount of protein 
mixed disulphides within a cell and if the concentration of protein mixed disulphides are 
too high then critical proteins such as receptors, protein kinases and transcription factors 
can be inactivated [41].  Because the amount of GSH and GSSG in the cell is critical for 
maintaining cellular homeostasis the ratio of GSH/GSSG is an important measure of 
oxidative stress [60].  A higher value of reduced GSH is considered to be healthy while a 
higher value of oxidized GSH is unhealthy [61].  GSH is involved in protecting cells 
from oxidative stress in a variety of ways including its use as a cofactor for detoxifying 
enzymes such as GPx and glutathione transferase.  In addition, GSH aids in amino acid 
transport through the plasma membrane and scavenges hydroxyl radicals and singlet 
oxygen using GPx, thereby clearing hydrogen peroxide and lipid peroxides from the cell.  
Moreover, GSH regenerates vitamin C and E into their active forms and GSH can reduce 
the tocopherol radical of vitamin E directly or indirectly [41, 62].   
 Other non-enzymatic mechanisms for defense against oxidative stress include 
vitamin E and C and less established molecules that exhibit antioxidant activity 
including carotenoids and related plant pigments, flavonoids and other phenolics.  α-
Tocopherol is the main component of vitamin E and is the most important antioxidant 
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located in membranes and lipoproteins involved in stopping the chain reaction of lipid 
peroxidation [63].  α-Tocopherol inhibits the lipid peroxidation chain reaction by 
scavenging peroxyl radical intermediates according to the following reaction : αTH + 
LOO˙             αT˙ + LOOH [64].  One of the products of the above reaction is an α-
tocopherol radical, however this radical is much less efficient at attacking fatty acid side 
chains that the peroxyl radical [65]. 
 Vitamin C is water soluble and one of the most important antioxidants present in 
extracellular fluids [66].  It has been demonstrated that vitamin C scavenges superoxide, 
hydrogen peroxide, hypochlorite, the hydroxyl radical, peroxyl radicals and singlet 
oxygen [67].  Studies with human plasma lipids have shown that vitamin C is more 
efficient as an inhibitor lipid peroxidation initiated by peroxyl radicals than other plasma 
components including α-tocopherol [68].  In addition, it was shown that vitamin C 
protects human sperm from oxidative DNA damage and vitamin C protects membranes 
from peroxidation by increasing α-tocopherol activity [69, 70].  In fact, vitamin C 
increases α-tocopherol activity by reducing the tocopherol radical generated when 
tocopherol participates in chain breaking of the lipid peroxidation reaction.  By reducing 
the tocopherol radical vitamin C restores the antioxidant activity of α-tocopherol [69, 
71].   
 Carotenoids can deactivate singlet oxygen and inhibit free radical reactions [72, 
73].  The antioxidant activity of carotenoids is due to their extended system of 
conjugated double bonds.  β-Carotene and lycopene are among the most effective 
carotenoids that quench singlet oxygen [74].  In addition to quenching singlet oxygen β-
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carotene and related carotenoids also inhibit free radical reactions by reduction of free 
radicals [72].   
 Flavonoids are involved in a variety of antioxidant defenses in vitro including 
inhibition of ROS formation by suppression of enzymes or by chelating trace elements 
involved in ROS production, scavenging ROS directly and upregulating antioxidant 
defenses [75].  Flavonoids inhibit enzymes involved in ROS formation including 
cyclooxygenases, lipoxygenases, microsomal monooxygenases, glutathione S-
transferases, mitochondrial succinoxidases, and NADH oxidase; flavonoids also chelate 
iron and copper, two pro-oxidant metals directly involved in the production of ROS [76, 
77].  Due to their low redox potentials flavonoids can also reduce oxidizing free radicals, 
such as superoxide, peroxyl, alkoxyl and hydroxyl radicals.  Overwhelming in vitro data 
suggests that flavonoids represent an essential class of natural compounds which 
function as cellular antioxidants, however a lack of in vivo data and inconsistent results 
concerning bioavailability question the utility of these phytochemicals and their use as 
neutriceuticals as “antioxidants”.   
     Positive roles of ROS 
 Although ROS, as described previously, damage proteins, lipids and nucleic 
acids it has also been demonstrated that ROS are involved in cell signaling and gene 
regulation [78].  In fact, at low cellular concentrations ROS can stimulate cell 
proliferation, while at high concentrations ROS can lead to growth arrest and cell death.  
Studies have shown that low concentrations of superoxide radicals and hydrogen 
peroxide stimulate cell proliferation in many cell types demonstrating that ROS acts as 
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secondary messengers in signal transduction pathways [79].  In addition, ROS mediates 
the function of a variety of intracellular signaling molecules including cytokines, non-
receptor tyrosine kinases, Ras, protein tyrosine phosphatases, serine threonine kinases 
and nuclear transcription factors including AP-1, NF-κB, p53, NFAT and HIF-1 [41].  
ROS are both beneficial and harmful to cells and therefore cellular antioxidants play a 
critical role in maintaining appropriate levels of ROS so that the cell may function 
normally.         
     ROS and cancer 
The production of ROS within the cell is inevitable due to normal metabolic 
functions and there is a defined range of ROS levels associated with cellular 
homeostasis.  When levels of ROS become too high cells have increased susceptibility to 
damage.  There is in vitro and in vivo evidence suggesting that cancer cells intrinsically 
have higher levels of ROS than normal cells [80-82].  In fact, increased stress in cancer 
cells due to ROS is correlated with aggressiveness of tumors and poor patient prognosis 
[83].  Studies have shown that solid tumors have increased levels of oxidized DNA bases 
(e.g. 8OHdG);  and lipid peroxidation products and malignant cells have lower levels of 
antioxidant enzymes such as SOD, GPx and peroxiredoxin [84].  There is no definitive 
mechanism to explain the increased levels of ROS within cancer cells, however there are 
many different mechanisms that contribute to the production of ROS in cancer cells such 
as the activation of oncogenes, unregulated metabolism, mitochondrial dysfunction, and 
loss of p53 [85-88].  In addition, a variety of genes, such as Ras, Bcr-Abl and c-Myc, 
whose expression is associated with tumor transformation can induce ROS production 
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[89].  Increased ROS stress in cells is known to lead to the initiation and progression of 
cancer and is thus viewed as a deleterious cellular effect, however excess levels of ROS 
in cancer cells can also be toxic and thus cancer cells exposed to high levels of ROS are 
more susceptible to damage and cellular death.  Therefore, manipulating ROS levels in 
cancer cells but not in normal tissues can be a potential mechanism to selectively kill 
cancer cells while causing minimal toxicity to non-cancer cells [90].   
     Drugs that induce ROS 
 There are a variety of anti-cancer drugs that induce ROS levels either by directly 
generating ROS or by depleting antioxidants thus leading to elevated levels of ROS.  
Examples of anti-cancer drugs that induce ROS production in cancer cells include 
arsenic trioxide, motexafin gadolinium, daunorubicin, doxorubicin, paclitaxel and 
elesclomol [91-93].  Compounds that target cellular antioxidants, such as GSH, include 
arsenic trioxide, celastrol, ascorbic acid, 2-cyano-3,12-dioxo-oleana-1,9-dien-28-oic acid 
methyl ester (CDDO-Me), isothiocyanates (ITCs) and buthionine sulfoxamine (BSO) 
[94-99].  In addition, there are many more compounds that target antioxidants such as 
SOD and thioredoxin.  Most of the above-mentioned drugs have been in pre-clinical or 
clinical trials and some have been approved for certain forms of cancer.  For instance, 
arsenic trioxide was approved for treatment of relapsing acute promyelocytic leukemia 
[1].  It is evident that the effective use of ROS-inducing compounds for treating a 
disease when, especially cancer, will require selective killing of the diseased cell and this 
must not be accompanied by acquired drug resistance.  Although it has been proven that 
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the compounds listed above regulate ROS production or through antioxidant depletion 
their overall mechanism of action as anti-cancer agents is not well defined.  
 Understanding the mechanism of action of a drug is critical for selective 
application of the agent to target critical pathways and is also essential for developing 
combined therapies.  Recently there have been many significant advances in elucidating 
the mechanism of action of some of the high profile ROS-inducing anti-cancer agents, 
such as arsenic trioxide, celastrol, ascorbic acid and CDDO-Me.  In fact, all four of these 
compounds have been shown to downregulate a family of transcription factors known as 
specificity protein (Sp) transcription factors through an ROS dependent mechanism  [94-
97].  Given that these compounds are drug candidates or are being used in clinical 
applications it is possible that other ROS-inducing compounds will share a comparable 
mechanism of action. 
     Sp transcription factors 
 Sp proteins belong to a family of zinc finger transcription factors known as 
Sp/Kruppel-like nuclear proteins [100].  Sp1-4 contain many structurally similar features 
including an activation domain, a C-terminal zinc finger DNA binding region, and an 
inhibitory domain in Sp3.  Sp5-8 are structurally similar to Sp1-4, however they possess 
an N-terminal truncation [101].  Sp proteins bind to and recognize DNA through GC/GT 
rich sequences using their C-terminal zinc finger DNA binding domain [102].  Because 
Sp proteins recognize GC rich sequences of DNA it has been demonstrated that Sp 
proteins are an important family of transcription factors that regulate a wide variety of 
mammalian genes [103].  In fact, gene knockout studies in mice showed that loss of Sp1 
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resulted in significant abnormalities including, retarded development and 
embryolethality on day 11 of gestation [104].  Gene knockout studies of Sp2 have not 
been reported and Sp3 knockout mice also exhibit growth retardation, tooth defects and 
death at birth [105].   Sp4 knockout mice die shortly after birth or survive with 
significant growth retardation [106].   Sp proteins regulate a wide variety of mammalian 
genes including several pro-oncogenic factors and not surprisingly these transcription 
factors play a critical role in tumor development, growth and metastasis [101].  
Knockdown of Sp1, Sp3, Sp4 or their combination by RNA interference has shown that 
Sp proteins regulate genes involved in growth (cyclin D1 (CD1)), survival (survivin), 
angiogenesis (vascular endothelial growth factor (VEGF), and their receptors, VEGFR1 
and VEGFR2) and anti-apoptosis (Bcl2) [46, 107-112].  In clinical studies it was shown 
that Sp1 expression was high in gastric tumor cells compared to normal glandular cells 
within or surrounding the tumor and that patients with high Sp1 expression had 
decreased survival compared to patients with low levels of Sp1 expression [113].  In 
addition, Sp1 expression was elevated in tumors from patients with pancreatic, breast, 
thyroid and colon cancer compared to normal tissues [114-117].  In many different 
forms of cancer high Sp expression is known to be a negative prognostic factor and thus 
Sp proteins represent a potential drug target for anti-cancer therapy [101].   
     Phenethyl isothiocyanate (PEITC) as a ROS-inducing anti-cancer agent 
As mentioned above, there are numerous compounds that are known to induce 
ROS.  Moreover, the mechanism of action of four of these compounds, arsenic trioxide, 
celastrol, ascorbic acid and CDDO-Me, have been elucidated in this laboratory in which 
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ROS is induced and subsequently results in downregulation of Sp1, Sp3 and Sp4 
proteins.  Isothiocyanates (ITCs) represent a class of anti-cancer drugs that have been 
studied extensively.  ITCs are a class of dietary phytochemical compounds generated 
from the hydrolysis of glucosinolates found in cruciferous vegetables, such as cabbage, 
kale, broccoli, cauliflower, brussels sprouts, kohlrabi, rape, black and brown mustard, 
and root crops including turnips and rutabagas [118, 119].  Studies in laboratory animals 
have shown that ITCs are effective in preventing various types of cancers including 
breast, lung, colon and prostate and epidemiological studies demonstrated that dietary 
consumption of ITCs in the form of cruciferous vegetables is associated with a reduced 
risk of cancer [120, 121].  In addition, ITCs are known to act not only as 
chemopreventitive agents but have also been demonstrated to act chemotherapeutically.  
Many different mechanisms of action have been proposed for ITC-induced cancer cell 
death, however no definitive mechanism has been identified.   
ITCs are highly electrophilic having a general structure of R-N=C=S.  The 
electron deficient central carbon atom in ITCs exposes them to nucleophilic attack by a 
variety of molecules including DNA/RNA, proteins and peptides [122].  Studies using 
14C labeled ITCs in A549 human non-small cell lung cancer cells showed no binding of 
ITCs to DNA/RNA suggesting that the primary target of ITCs are proteins [123].  Thiol 
groups of proteins and peptides are the primary target of the electrophilic center in ITCs 
and for this reason ITCs are able to conjugate with many different cellular proteins and 
one of the most significant targets of ITCs is glutathione.  ITCs readily bind to and 
conjugate with glutathione forming the glutathione conjugate, S-(N-
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alkyl/arylthiocarbamoyl) glutathione.  Once formed the glutathione conjugate proceeds 
through the mercapturic acid pathway and is excreted in the urine [118].  By conjugating 
to and thus depleting glutathione levels in the cell, ITCs induce ROS thereby causing 
oxidative stress and cell death.  Based on the results in this laboratory regarding the 
mechanism of action of arsenic trioxide, celsastrol, ascorbic acid and CDDO-Me, we 
hypothesize that compounds that induce ROS in turn downregulate Sp proteins and this 
mechanism is due to ROS-dependent downregulation of microRNA-27a (miR-27a) 
and/or miR-20a/miR-17-5p and this is accompanied by induction of the miR-regulated 
Sp repressors ZBTB10 and ZBTB4, respectively 
Part two 
Reactive oxygen species (ROS) includes radicals such as superoxide, nitric oxide 
and hydroxyl radicals and non-radical species including hydrogen peroxide, ozone and 
peroxynitrate and these molecules function in normal cells to maintain homeostasis via 
redox pathways [124-128]. In some cancer cell lines a modest increase in forms of ROS 
can enhance cell proliferation, survival and drug resistance, however further increases in 
ROS that cannot be attenuated by intracellular redox systems can lead to cell death 
[128]. ROS levels are higher in cancer vs. non-cancer cells and drug-induced elevation 
of ROS is a “way to selectively kill cancer cells without causing toxicity to normal cells” 
[128]. Drug-induced ROS in cancer cells may be due to inhibition or inactivation of 
redox pathway enzymes or by direct effects on mitochondria which includes opening of 
the permeability transition pore complex, decreased mitochondrial membrane potential 
(MMP) and release of ROS and proapoptotic factors [128-133]. Many clinically used 
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anticancer agents such as arsenic trioxide induce ROS as a primary mechanism of action 
and other highly effective or promising drugs including curcumin and other 
phytochemicals and synthetic analogs such as 2-cyano-3,12-dioxo-oleana-1,9-dien-28-
oic acid (CDDO) induce ROS in some cancer cells and tumors and this response 
contributes to their anticancer activities [134-150]. 
Several studies demonstrate that consumption of cruciferous vegetables is 
associated with a decreased incidence of some cancers [151-155] and the expression of 
various isothiocyanates (ITCs) has been linked to cancer chemoprevention by 
cruciferous vegetables. ITCs including 1-isothiocyanato-4-(methylsulfinyl) butane 
(sulforaphane), benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC) and 
allyl isothiocyanate (AITC) have been extensively investigated as anticancer agents, and 
ITCs inhibit several pathways associated with cancer cell growth, survival, inflammation 
and angiogenesis/metastasis [156-175]. Modulation of these pathways by ITCs has been 
linked to downregulation of total and activated STAT3 protein [165] suppression of 
NFкB (and p65 downregulation) [166-168], decreased expression of epidermal growth 
factor receptor (EGFR) [169], migrations/invasion factors [171, 172], Bcl-2 [175], 
cyclins [160,175, 176] and modulation of kinase activities. Many of these ITC-induced 
responses in pancreatic and other cancer cell lines are also accompanied by decreased 
mitochondrial membrane potential (MMP) and/or induction of  (ROS); and the effects 
can be attenuated, in part, by cotreatment with antioxidants [156-164, 177]. The 
potential clinical applications of ITCs for cancer chemotherapy will depend on a more 
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detailed understanding of their underlying mechanisms of action which is necessary for 
development of effective drug combinations. 
Recent studies in this laboratory have demonstrated that several anticancer drugs 
that induce ROS including arsenic trioxide the methyl ester of CDDO (CDDO-Me), 
betulinic acid, a synthetic nitro-non-steroidal antiinflammatory drug (GT-094) and 
celastrol also downregulate specificity protein (Sp) transcription factors Sp1, Sp3 and 
Sp4 and pro-oncogenic Sp-regulated genes [178-181]. Similar results have also been 
observed for H202, t-butylhydroperoxide and pharmacologic doses of ascorbate that 
induce H202 [180, 182-184] and the effects of ROS inducers and the prooxidants on 
downregulation of Sp proteins, Sp-regulated genes, growth inhibition and induction of 
apoptosis are attenuated after cotreatment with antioxidants. Moreover, induction of 
ROS by CDDO-Me, GT-094, betulinic acid and celastrol downregulated Sp transcription 
factors through downregulation of microRNA-27a (miR-27a) or miR-17-5/miR-20a and 
induction of the miR-regulated Sp repressors ZBTB10 and ZBTB4 respectively [178-
181]. The relationship between drug-induced ROS and disruption of miR-ZBTB 
interactions observed for these compounds suggests general mechanisms of action for 
other ROS-inducing anticancer agents and this concept was further investigated using 
PEITC as a model. The mechanisms of action PEITC has been extensively studied in 
cancer cell lines.  Ras transformed ovarian cells PEITC decreases intracellular GSH and 
also directly inhibits glutathione peroxidase resulting in the induction of ROS and 
decreased MMP [163]. In this study we have investigated the anticancer activity of 
PEITC in pancreatic cancer cells and show that like other ROS inducers PEITC 
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decreased expression of Sp1, Sp3 and Sp4 through disruption of miR-ZBTB interactions 
demonstrating the important contributions of this pathway to their anticancer activity of 
PEITC. 
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MATERIALS AND METHODS 
Cell lines, reagents and antibodies 
The Panc-28 cell line was a generous gift from Dr. Paul Chiao (University of 
Texas M.D. Anderson Cancer Center, Houston, TX).  The L3.6pL cell line was 
developed at the M.D. Anderson Cancer Center (Houston, TX) and was kindly provided 
by Dr. I.J. Fidler.  Panc-1 cells were obtained from the American Type Culture 
Collection (Manassas, VA).  All above-mentioned cells were maintained in Dulbecco’s 
modified/Ham’s F-12 (Sigma Aldrich, St. Louis, MO) with phenol red supplemented 
with 0.22% sodium bicarbonate, 5% fetal bovine serum and 10 ml/L 100X 
antibiotic/antimycotic solution (Sigma).  The cells were grown in 150 cm2 culture plates 
in an air/CO2 (95:5) atmosphere at 37°C and passaged approximately every 3-5 days.  
Survivin and CD1 was purchased from Epitomics (Burlingame, CA); VEGF from 
Rockland (Gilbertsville, PA); CPARP and C-myc from Cell Signaling (Boston, MA); 
and VEGFR1 from Abcam (Cambridge, MA).  All other antibodies were purchased from 
Santa Cruz (Santa Cruz, CA).  Glutathione, 98% (γ-Glu-Cys-Gly, GSH) and PEITC 
(99% pure) were purchased from Sigma Aldrich.  Chemiluminescence reagents 
(Immobilon Western) for western blot imaging were purchased from Millipore 
(Billerica, MA). 
Cell proliferation assay 
Pancreatic cancer cells (4 x 104 per well) were plated in 12-well plates and 
allowed to attach for 24 h. The medium was then changed to DMEM/ Ham's F-12 
medium without phenol red containing 2.5% charcoal-stripped FBS, and either vehicle 
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(DMSO) or different concentrations of compounds were added. Cells were then 
trypsinized and counted after 24, 48 and 72 h using a Coulter Z1 cell counter. Pancreatic 
cancer cells (1.5 X 105 per well) were plated in 12-well plates and allowed to attach for 
24 h.  The medium was changed to DMEM/Ham’s F-12 medium without phenol red 
containing 2.5% charcoal-stripped FBS and cells were pre-treated with GSH for 45 min.  
After pre-treatment cells were either dosed with PEITC alone or co-treated with PEITC 
and GSH.  Cells were trypsinized and counted after 24 h using the Coulter Z1 cell 
counter.  Each experiment was done in triplicate, and results were expressed as means ± 
SE for each set of experiments. 
Western blot analyses 
Pancreatic cancer cells were seeded in DMEM/ Ham's F-12 medium 
supplemented with 2.5% fetal bovine serum.  After 24 h, cells were pre-treated with 
GSH for 45 min.  After pre-treatment cells were dosed with vehicle (DMSO) and PEITC 
alone or co-treated with PEITC and GSH for the indicated time.  The tumor tissues from 
the L3.6pL pancreatic cancer xenograft study were also processed similarly and probed 
for proteins ofinterest and β-actin served as the loading control.  Cells were lysed using 
high-salt lysis buffer containing 50 mmol/l N-2-hydroxyethylpiperazine-NꞋ-2-
ethanesulfonic acid, 0.5 mol/l sodium chloride, 1.5 mmol/l magnesium chloride, 1 
mmol/l ethyleneglycol-bis(aminoethylether)-tetraacetic acid, 10% (vol/vol) glycerol, 1% 
Triton X-100 and protease inhibitor cocktail, 1:1000 (Sigma). Lysates were collected 
and vortexed every 15 sec for 1 h. The lysates were then centrifuged at 20,000 X g for 
10 min at 4◦ C and quantified with Bradford reagent. Equal amounts of protein from each 
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treatment group were separated on 7.5 and 7.5/12% sodium dodecyl sulphate-
polyacrylamide gel (SDS-PAGE) at 150 V for 5 h. Proteins were then transferred onto 
polyvinylidene difluoride (PVDF) membranes (Biorad, Hercules, CA) by wet 
electroblotting and the membranes were blocked with 5% milk in buffer containing 
1.576 g/l Tris, 8.776 g/l sodium chloride and 0.5 ml/l Tween 20. The PVDF membranes 
were then probed with primary antibodies, followed by incubation with horseradish 
peroxidase-conjugated secondary antibodies as indicated. Membranes were then 
incubated with Immobilon Western chemiluminescence substrates (Millipore, Billerica, 
MA) and images were captured on a Kodak 4000 MM Pro image station.  
Measurement of MMP 
The MMP was measured with a Mitochondrial Membrane Poten-tial Detection 
Kit (Stratagene,CedarCreek,TX).  Briefly, cells were seeded on Lab-Tek Coverglass 
system (NUNC,NY) and treated with PEITC alone or co-treated with GSH for the 
indicated time.  They were then incubated with 1×JC-1 cationic dye at 37°C for 30 min. 
according to the manufacturer's instructions.  After washing with 1×JC-1 assay buffer 
twice, cells were subjected to microscopic analysis using a confocal instrument (Carl 
Zeiss, Thornwood, NY).  J-aggregates are detected as red fluorescence and J-monomers 
are detected as green fluorescence. 
ROS estimation 
Cellular ROS levels were evaluated with the cell permeable probe 
CM-H2DCFDA(5-(and-6)-chloromethyl-2′,7′ dichlorodihydrofluorescein diacetate 
acetyl ester).  CM-H2DCFDA is non-fluorescent until removal of the acetate groups by 
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intracellular esterases and subsequent oxidation occurs within the cell.  Cells were 
seeded at a cellular density of 1 X 105 cells/mL in 6 well plates and were allowed to 
attach for 24 h.  After 24 h cells were pre-treated with GSH for 45 min.  After pre-
treatment cells were treated with vehicle (DMSO) or with PEITC alone or co-treated 
with PEITC and GSH for the indicated time.  After the indicated amount of time cells 
were trypsinized and neutralized with Dulbecco’s modified/Ham’s F-12 medium 
supplemented with 5% fetal bovine serum.  Cells were collected in tubes and were spun 
for 5 min at 0.1 rcf to pellet the cells.  The supernatant was discarded and cells were 
resuspended in Dulbecco’s modified/Ham’s F-12 medium without 0% serum with 10uM 
CM-H2DCFDA.  Cells were incubated with dye for 30 min. at 37°C with 5% CO2.  
After incubation, cells were spun down at 0.1 rcf for 5 min.  The supernatant was 
removed and cells were washed three times with Dulbecco’s modified/Ham’s F-12 
medium.  Immediately before analysis 100 nM propidium iodide was added to the cells 
to measure the number of dead cells compared to live cells.  Cells were analyzed by flow 
cytometric analysis using a BD Accuri-C6 Flow Cytometer (BD Biosciences, San Jose, 
CA).  Cells were collected at a fast fluidics rate at a count of 30,000 cells.  Data was 
analyzed using Cflow and FloJo analysis software.  
Annexin V staining 
Pancreatic cancer cells (1 × 105) were seeded in 2 well chambered glass slides 
and left to attach overnight.  The apoptotic and necrotic assay kit was obtained from 
Biotium, Inc.(Hayward, CA) and contained FITC-Annexin V, ethidium homodimer III, 
and Hoechst 3342.  Cells were pre-treated with GSH for 45 min.  After pre-treatment 
 
 
27 
 
cells were dosed with vehicle and PEITC alone or PEITC with GSH for the indicated 
time.   The apoptotic, necrotic, and healthy cell detection kit was used according to the 
instructions provided by the manufacturer for analysis of adherent cells.  
Transmission electron microscopy 
Cells were seeded at a cellular density of 1 X 105 cells/mL in Dulbecco’s 
modified/Ham’s F-12 medium with 2.5% fetal bovine serum in Permanox 2-well 
chambered slides.  Cells were pre-treated with GSH for 45 min.  After pre-treatment 
cells were treated with vehicle (DMSO) and PEITC alone or co-treated with PEITC and 
GSH for the indicated time.  After dosing, cell cultures were fixed in 2% glutaraldehyde 
and 2.5% paraformaldehyde in 0.1 M sodium cacodylate buffer for 1 hr at room 
temperature.  After washing in buffer the cell monolayers were post stained with 1% 
osmium tetroxide reduced by 0.2% potassium ferrocyanide for 1 h then dehydrated in an 
ascending alcohol series and embedded in epoxy resin.  Thin sections were cut en face, 
stained with 2% uranyl acetate and Reynold’s lead citrate and then examined with an 
FEI Morgagni 268 transmission electron microscope (FEI, Hillsoboro, OR) at an 
accelerating voltage of 80 kV.  Digital images were acquired with a MegaViewIII 
camera operated with iTEM software (Olympus Soft Imaging Systems, Munster, 
Germany) then post-processed with Adobe Photoshop. 
Real-time PCR 
Total RNA was isolated using the mirVana miRNA Isolation Kit (Ambion, 
Austin, TX) according to the manufacturer's protocol.  RNA was eluted with 100 μl of 
RNase-free water and stored at -80˚C. RNA was reverse transcribed using Superscript II 
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reverse transcriptase (Invitrogen, Carlsbad, CA) according to the manufacturer's 
protocol. cDNA was prepared from the pancreatic cancer cell lines using a combination 
of oligodeoxythymidylic acid (Applied Biosystems, Foster City, CA), dNTP mix  and 
Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA).  All microRNA’s were 
purchased from Applied Biosystems. 
SiRNA interference assay 
Pancreatic cancer cells were seeded (1 × 105 per well) in six-well plates in 
DMEM/Ham's F-12 medium supplemented with 2.5% charcoal-stripped FBS without 
antibiotic and left to attach for 1 day. C-myc (Sigma Aldrich SASI 
_Hs01_00222676 and SASI_Hs01_00222677) along with iLamin as a control was 
performed using Lipofectamine 2000 as the carrier reagent according to the 
manufacturer's instructions. Small inhibitory RNAs were prepared by Sigma-Aldrich. 
Statistical analysis 
Statistical significance of differences was determined by an 
analysis of variance and student t-test, and the levels of probability were noted. 
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RESULTS 
Initial studies showed that PEITC inhibited growth of Panc1, L3.6pL and Panc28 
cells after treatment for 1, 2 or 3 days and growth inhibition after treatment for 24 hr was 
observed for 20 µM PEITC in all cell lines and 10 µM PEITC also significantly 
inhibited growth in L3.6pL and Panc28 cells (Fig. 1A).  
The concentrations of PEITC required for inhibition of pancreatic cell growth 
were slightly higher than previously reported in prostate and bladder cancer cells and 
this was also confirmed in this study (data not shown). Subsequent in vitro cell culture 
experiments primarily used 20 µM PEITC since the major focus of this study was on the 
primary mechanism of action of PEITC and early events that occur (within 24 hr) after 
treatment. Induction of ROS by 20 µM PEITC was investigated in Panc1, L3.6pL and 
Panc28 cells by FACS analysis using the cell permeant probe carboxy-H2DCFDA (Figs. 
1B) ROS were induced by PEITC after treatment for 3 or 6 hr and in cells co-treated 
with PEITC plus the antioxidant GSH induction of ROS by PEITC was significantly 
inhibited.  
Not surprisingly the magnitude of ROS induction varied among the 3 cell lines. 
The rapid induction ROS by PEITC is consistent with a previous report in oncogenically 
transformed cells where PEITC rapidly depleted intracellular GSH and inhibited 
glutathione peroxidase enzyme activity in cells and a cell-free system [163] and these 
effects contributed to induction of ROS by this ITC. 
The effects of PEITC on mitochondrial structure and integrity in pancreatic 
cancer cells were examined by transmission electron microscopy (TEM). Initial studies 
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with L3.6pL cells treated with 20 µM PEITC for 1, 3 or 6 hr showed that significant loss 
of mitochondrial architecture and cristae structure which was observed only after 
treatment for 6 hr and in L3.6pL cells co-treated with GSH the mitochondrial damage 
was reversed (Fig. 2A). A similar approach was used for Panc1 (Fig. 2B) and Panc28 
(Fig. 2C) cells and the results showed that mitochondrial structural damage was 
observed after induction of ROS (3 hr) and this damage was also attenuated after co-
treatment with GSH (TEM time course results for L3.6pL, Panc1 and Panc28 cells 
coming).  
The ROS-mediated mitochondrial damage in pancreatic cancer cells treated with 
PEITC was further investigated by determine the effects of PEITC on loss of 
mitochondrial membrane potential (MMP) using the JC-1 dye and by determining the 
JC-aggregates (red fluorescence)/JC-monomer (green fluorescence) ratios. Several 
different time points were investigated and MMP was not decreased after treatment for 3 
hr (data not shown) results in Figures 2D-2F show results in L3.6pL (6 hr), Panc1 (12 
hr) and Panc28 (12 hr) respectively at the earliest time points for PEITC-mediated 
effects on MMP. PEITC clearly decreased MMP in all 3 cell lines and co-treatment with 
the antioxidant GSH significantly inhibited this response further demonstrating the 
important role of PEITC-induced ROS in subsequent mitochondrial damage.  The 
cytotoxic effects of PEITC-induced ROS was further examined by determining the 
effects of PEITC in the absence or presence of GSH on Annexin V staining (apoptosis) 
and cell proliferation. PEITC clearly induced Annexin V staining in Panc1, L3.6pL and 
Panc28 cells (Figs. 3A-3C) and  this response was significantly blocked in cells co-
Fig. 2C Fig. 2D 
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treated with GSH; moreover, GSH also attenuated PEITC-induced growth inhibition 
(Fig. 3D) confirming that PEITC-induced ROS plays an essential role in the anticancer 
activity of this compound in pancreatic cancer cells.  Previous studies in this laboratory 
show that ROS-inducing anticancer agents BA, celastrol and CDDO-Me (all 
triterpenoids) and the NO-NSAID GT-094 decrease expression of Sp transcription 
factors [178-181] and therefore the effects of PEITC or expression of Sp1, Sp3, Sp4 and 
Sp-regulated gene products were also determined. \Treatment of L3.6pL, Panc1 and 
Panc28 cells with 10 or 20 µM PEITC for 24 hr decrease levels of Sp1, Sp3 (low and 
high molecular weight forms) and Sp4 proteins (Fig. 4A) and this was consistent with 
results of previous studies with ROS inducers [178-181].   Moreover, the effects on Sp 
proteins were accompanied by downregulation of survival genes products Bcl-2 and 
survivin and induction of PARP cleavage (Fig. 4B) and downregulation of growth 
promoting (cyclin DL and EGFR) and angiogenic (VEGF and VEGFR1) proteins (Fig. 
4C).  We also observed that PEITC-induced downregulation of Sp1, Sp3 and Sp4 
proteins was reversed in L3.6pL, Panc1 and Panc28 cells co-treated with PEITC plus 
GSH (Fig. 4D) confirming a role for ROS in mediating repression of Sp transcription 
factors and this correlated with the role of ROS in PEITC-induced apoptosis and growth 
inhibition in pancreatic cancer cells (Fig. 3). 
The role of ROS-dependent disruption of miR-ZBTB interactions was 
investigated in pancreatic cancer cells treated with 20 µM PEITC for 24 hr. Figure 5A 
shows that in L3.6pL, Panc28 and Panc1 cells treatment with PEITC decreased 
expression of miR-27a, miR-17-5p and miR-20 and in cells treated with PEITC plus the 
Fig. 3A 
Fig. 3C 
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cantioxidant GSH significantly attenuated downregulation of the miRs (Fig. 5B).  
Similar results were previously observed for celastrol in bladder cancer cells [181]. 
Preliminary studies in Panc28 cells showed minimal induction of ZBTB10 or ZBTB4 
gene expression and after screening several related transcriptional repressors we 
identified ZBTB34 as a PEITC-inducible gene. Figure 5C demonstrates that PEITC 
induced expression of ZBTB34 (results coming) on L3.6pL, ZBTB10 and ZBTB34 in 
Panc28 and ZBTB4 and ZBTB10 in Panc1 cells.  Moreover, in cells co-treated with 
PEITC plus GSH, induction of the transcriptional repressors is attenuated (Fig. 5D). 
Thus like celastrol GT-094, betulinic acid and CDDO-Me in bladder, colon and 
pancreatic cancer cells [178-181], PEITC also induced ROS-dependent downregulation 
of miRs in pancreatic cancer cells.  
A recent study showed that ROS-induced genome wide shifts in repressor 
complexes in colon cancer cells resulting in decreased expression of Myc [185] which 
regulates expression of multiple miRs including miR-27a and miR-20a/miR-17-5p 
which are members of the miR-17-92 cluster [186-188]. L3.6pL cells were used as a 
model and treatment with PEITC decreased expression of Myc protein within 3 hr after 
treatment and the decrease was observed for up to 12 hr (Fig. 6A).  Surprisingly we also 
observed similar effects of PEITC on Sp1 (but not Sp3 or Sp4) and downregulation of 
Myc and Sp1 were reversed in cells co-treated with PEITC plus glutathione. The role of 
Myc in downregulation of Sp1, Sp3 and Sp4 was confirmed by RNAi in L3.6pL cells; 
knockdown of c-Myc by two oligonucleotides (i-c-Myc1/i-c-Myc2) showed that 
Panc-28 
L3.6pL 
Fig. 5B 
Fig. 6A 
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decreased expression of the oncogene resulted in downregulation of Sp1, Sp3 (high MW 
form only) and Sp4 proteins (Fig. 6B). 
Current studies are focused on  knockdown of c-Myc and Sp1 by RNAi to 
determine their effects on Sp proteins miR-27a, miR-20a, miR-17-5p, ZBTB10 and 
ZBTB4 and also PEITC-mediated changes in histone methylation marks associated with 
regulation of c-Myc and Sp.   
The effects of PEITC on pancreatic tumor growth were determined in athymic 
nude mice bearing L3.6pL cells as xenografts. PEITC (60 mg/kg/d) decreased tumor 
growth and weight (Fig. 7A). 
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CONCLUSIONS 
 Sp1, Sp3 and Sp4 transcription factors are highly expressed in cancer cells and 
tumors [178-184], and studies focused on Sp1 show that this protein is a negative 
prognostic factor for pancreatic and gastric cancer patient survival [189-191] and Sp1 
expression is critical for malignant transformation of human fibroblast cells [192]. 
Expression of Sp transcription factors in rodent and human tissues decreases with age 
[153-155] and the high tumor/non-tumor ratio of Sp1 suggests that Sp proteins are 
important drug targets for cancer chemotherapy. Knockdown of Sp1, Sp3 and Sp4 alone 
or in combination by RNAi also decreased expression of several genes involved in 
cancer cell growth (cyclin D1, c-MET, EGFR), survival (bcl-2 and survivin), 
angiogenesis (VEGF and VEGF receptors), and inflammation (p65, NFкB), and many of 
these genes are themselves targets for anticancer drugs. Moreover, knockdown of Sp 
transcription factors in cancer cells alone also induces apoptosis and growth inhibition 
[180-182], and carcinogen-induced transformed fibrosarcoma cells that form tumors in 
nude mice lose their tumorigenicity after knockdown of Sp1 [192]. Several clinically 
used anticancer agents and experimental drugs downregulated Sp1, Sp3 and Sp4 proteins 
and pro-oncogenic Sp-regulated gene products in cancer cell lines through multiple 
pathways and these are dependent on the drug and cell context. For example curcumin 
induces proteasome-dependent downregulation of Sp proteins in bladder cancer cells 
whereas in pancreatic cancer cells the effects of curcumin are ROS-dependent and are 
attenuated after co-treatment with antioxidants [182, 193]. 
Fig. 7 
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Previous studies with PEITC and related ITCs show that the compounds inhibit 
cancer cell growth and angiogenesis/invasion, induced apoptosis and also decreased 
expression of several gene products such as p65 (NFкB0, bcl-2, cyclin and EGFR that 
are also Sp-regulated genes [166-176]. The mechanisms of action of PEITC are both 
ROS-dependent and independent in different cancer cell lines and the ROS-mediated 
effects have been extensively investigated [158, 159, 163, 177]. For example, PEITC 
rapidly depleted intracellular GSH and inhibited glutathione peroxidase activity and the 
subsequent induction of ROS decreased MMP which was accompanied by induction of 
apoptosis [163]. PEITC also induced ROS and decreased MMP in bladder and prostate 
cancer cells [159, 161, 162, 169] through slightly different pathways which involved 
cytochrome c release and changes in mitochondrial proteins.  In prostate cancer cells it 
was suggested that PEITC directly affected mitochondrial oxidative phosphorylation 
[162]. In pancreatic cancer cells PEITC rapidly induced ROS (within 3 hr) (Figs. 1B-1D) 
and using TEM we also showed that PEITC did not significantly affect mitochondrial 
ultrastructure until 6 hr after treatment (Fig. 2).  Similar results were observed for MMP 
which were only decreased after ≥ 6 hr (Fig. 2). These results coupled with the 
protective effects of GSH are consistent with an initial mechanism of 
extramitochondrial-induced ROS by PEITC as observed in H-Ras transformed ovarian 
epithelial cells [163].  
The central role of ROS in the anticancer activity of PEITC in pancreatic cancer 
cells was confirmed by the effects of GSH on reversing PEITC-induced cell death and 
cell proliferation (Fig. 3). Previous studies with PEITC, related ITCs and many other 
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ROS inducers have demonstrated that induction of extra- or intra-mitochondrial ROS is 
associated with mitochondrial damage which is linked to activation of apoptosis. In 
contrast, several ROS inducers, H202 and other pro-oxidants also induce downregulation 
of Sp1, Sp3, Sp4 and pro-oncogenic Sp-regulated genes and gene products in cancer cell 
lines [178-185].  In this study we have observed similar PEITC-induced effects which 
are attenuated by cotreatment with glutathione (Fig. 4). Since knockdown of Sp1 and 
other Sp proteins by RNA interference in pancreatic cancer and other cancer cell lines 
results in growth inhibition, induction of cell death and inhibition of tumor growth in 
vivo [180-182, 192] then the anticancer activity of PEITC on pancreatic cancer cells is 
due not only to apoptosis resulting from mitochondrial damage but also to 
downregulation of Sp transcription factors and Sp-regulated genes. 
The high expression of Sp1, Sp3 and Sp4 in cancer cell lines is due to 
microRNA-dependent suppression of transcriptional repressors ZBTB10 and ZBTB4 
which competitively bind GC-rich promoter sites to displace Sp proteins [194]; this 
results in decreased transcription since ZBTB10 and ZBTB4 do not express 
transactivation domains. ZBTB10 expression is repressed by miR-27a [195] and ZBTB4 
is repressed by miR-20a and miR-17-5p (part of the miR-17-92 cluster) and other 
paralogs [195].  PEITC/ROS-mediated downregulation of miR-27a and/or miR-
20a/miR-17-5p results in induction of ZBTB10 and ZBTB4 and subsequent 
downregulation of Sp proteins [178-181]. Similar results were observed using the 
antagomirs or overexpression of ZBTB10 or ZBTB4 [194,195]. Figure 5 illustrates that 
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PEITC also disrupts the miR-ZBTB circuits through an ROS-dependent pathway in 
which the effects of ROS are attenuated by antioxidants. 
These results demonstrate that PEITC, other ROS inducers (e.g. betulinic acid, 
GT-094, celastrol, CDDO-Me and curcumin) and prooxidants, activate a common 
pathway in cancer cells resulting in the induction of ZBTB10 and/or ZBTB4 through 
ROS-dependent downregulation of miR-27a and miR-20a/miR-17-5p. This is an 
important mechanism of action for PEITC and other ROS-inducing anticancer agents 
since this also activates downregulation of Sp transcriptions which play a role in cancer 
cell growth, survival, metastasis and inflammation. The key unknown link between 
induction of ROS and downregulation of miRs is the mechanism associated with miR 
downregulation. A recent study reported that treatment of colon cancer cells with H202 
results in relocation of large chromatin-associated repressor complexes from non-GC 
rich to GC-rich sites and that genes with GC-rich promoters such as Myc were 
downregulated [185]. Using L3.6pL cells as a model (Fig. 6) we showed that PEITC 
downregulated c-Myc and Sp1 proteins as early as 3 hr after treatment and this response 
was also reversed in cells co-treated with PEITC plus GSH. These data coupled with the 
effects of c-Myc knockdown on Sp proteins (and induction of ZBTB4) (Fig. 6) suggest 
that in pancreatic cancer cells ROS may induce comparable shifts in repressor 
complexes observed in colon cancer cells [185]. Moreover, the decreased expression of 
Myc is consistent with downregulation of miR-27a and miR-20a/miR-17-5p which are 
members of 2 Myc-regulated miR clusters [186-188]. 
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Therefore, we demonstrate for the first time that an important component of the 
anticancer activity of ROS inducers, namely downregulation of Sp1, Sp3, Sp4 and pro-
oncogenic Sp-regulated gene products is due to ROS-induced epigenetic effects which 
results in repression of the c-Myc oncogene. Currently we are further analyzing 
methylation marks associated with ROS-medicated regulation of c-Myc and evaluating 
the role of c-Myc, Sp1 and other factors as essential downstream responses to ROS-
induction by anticancer agents in different cancer cell lines.  
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Figure 1.  PEITC inhibits pancreatic cancer cell growth and induces ROS. A.  L3.6pL, 
Panc28 and Panc1 cells were treated with different concentrations of PEITC for up to 72 
hr and cells were counted as outlined in the Materials and Methods. Panc1, L3.6pL and 
Panc28` cells were treated with 20 µM PEITC, GSH or their combination for 3 and 6 hr 
and ROS was determined by FACS analysis using the cell permeant CM-H2DCFDA as 
described in the Materials and Methods. The colors represent treatment as follows: 
red=DMSO, blue=20uM PEITC, orange=GSH, green=co-treatment. Results in A are 
means ± SE (3 replicates) and significant (p < 0.05) inhibition is indicated (*). 
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Fig. 2F 
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Figure 2.  PEITC disrupts mitochondrial structure and decreases MMP. L3.6pL (A), 
Panc1 (B) and Panc28 (C) cells were treated with 20uM PEITC for different times and 
mitochondrial structure was determined by TEM as outlined in the Materials and 
Methods. D. Cells were treated with DMSO (solvent), 20 uM PEITC, 5 mM GSH or in 
combination for 6 hr and mitochondrial structure was determined as outlined in 
Materials and Methods.  The effects of PEITC, GSH alone or in combination on MMP 
was determined L3.6pL (E), Panc1 (F) and Panc28 (G) cells by JC-1 staining as outlined 
in the Materials and Methods.  Results (E-G) are means ± SE (3 replicates per data 
point) and significant (p < 0.05) inhibition (*) or reversal of the effect by GSH (**) is 
indicated. 
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Figure 3.  Glutathione inhibits PEITC-induced apoptosis and growth inhibition. Panc1 
(A), L3.6pL (B) and Panc28 (C) cells were treated with 20 µM PEITC, GSH alone or in 
combination and Annexin V staining was determined as outlined in the Materials and 
Methods. D. Cells were treated for 24 hr and cells were counted as outlined in the 
Material and Methods. Results are means ± SE (3 replicates for each data point) and 
significant (p < 0.05) effects by PEITC (*) and attenuation by cotreatment with GSH (**) 
are indicated. 
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Figure 4.  PEITC downregulates Sp1, Sp3, Sp4 and Sp-regulated genes. Pancreatic 
cancer cells were treated with different concentrations of PEITC for 24 hr and whole cell 
lysates were analyzed for Sp1, Sp3 and Sp4 proteins (A) prosurvival proteins (B), 
growth promoting and angiogenic proteins (C) by western blots as outlined in the 
Materials and Methods. D. Cells were treated with PEITC, GSH alone or in combination 
for 24 hr and cell lysates were analyzed by Western blots as indicated in A-C. Results in 
this figure are from one of at least duplicate analyses which gave comparable results. 
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Figure 5.  PEITC disrupts miR-ZBTB circuits. A. Pancreatic cancer cells were treated 
with PEITC for 24 hr and miR levels were determined as outlined in the Materials and 
Methods. B. Pancreatic cancer cells were treated with PEITC and GSH alone and in 
combination for 24 hr and miR levels were determined as described in the Materials and 
Methods. Using the same protocol as described in A/B the effects of PEITC alone (C) 
and PEITC plus GSH (D) on expression of ZBTB10, ZBTB4 and ZBTB34 mRNA 
levels were determined by real time PCR as described in the Materials and Methods. 
Results are means ± SE for at least 3 replicates per determination and significant (p < 
0.05) effects of PEITC alone (*) or attenuation of the effects by GSH (**) are indicated. 
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Figure 6.  Role of c-Myc in PEITC-induce downregulation of Sp proteins. A. L3.6pL 
cells were treated with 20 µM PEITC alone or in combination with GSH for 3, 6 and 12 
hr and whole cell lysates were analyzed by Western blots as described in the Materials 
and Methods. B. L3.6pL cells were transfected with oligonucleotides (i-c-Myc-1-i-c-
Myc-2) targeted against c-Myc and whole cell lysates were analyzed by Western blots as 
outlined in the Materials and Methods. 
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Figure 7.  PEITC as an inhibitor of pancreatic tumor growth. A. Athymic nude mice 
bearing L3.6pL cells as xenografts were administered PEITC (60mg/kg/d) and after 12 
days tumors and organs were excised and weighed as described in the Materials and 
Methods B.  
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